Tech Company Financing Transactions
Odimma Therapeutics Funding Round
Alsace Business Angels, Angels Santé and Bpifrance invested in a $2.2 million Seed capital raise for Odimma Therapeutics. The round was announced on 5/3/2023.
Transaction Overview
Company Name
Announced On
5/3/2023
Transaction Type
Venture Equity
Amount
$2,206,000
Round
Seed
Proceeds Purpose
The company intends to use the funds to secure the preparation on its First-in-Man clinical trial with ODI-2001, an innovative first-in-class personalized immunotherapy against cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
PH8 - 8 place de l'Hôpital
Strasbourg, 67000
FR
Strasbourg, 67000
FR
Phone
Undisclosed
Website
Email Address
Overview
Translating patient uniqueness into unique patient treatments with an innovative personalised immunotherapy platform based on artificial intelligence and synthetic DNA technology. One of the major hurdles in the fight against cancer is that each tumour is genetically unique and has specific tumour markers.Odimma has designed a next-generation precision immunotherapy platform able to induce a powerful cellular immune response against specific tumours markers as well as a strong anti-tumoural effect in several aggressive models such as melanoma, colorectal and breast cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Jean Limacher
Chief Executive Officer
Jessica Matta
Browse more venture capital transactions:
Prev: 5/3/2023: Gigs venture capital transaction
Next: 5/3/2023: Cohere venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs